Strides Pharma Science’s arm receives approval for Triamcinolone Acetonide Cream

Strides Pharma Science’s step‐down wholly owned subsidiary — Strides Pharma Global, Singapore, has received approval for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% from the United States Food & Drug Administration (USFDA).

The product is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc. According to IQVIA MAT data, the US market for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is approximately $55 million. The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.